A 32-year-old woman with newly diagnosed acute promyelocytic leukaemia (APL) is started on all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). On day 5 of treatment, she develops fever (38.5°C), dyspnoea, and hypoxia (SpO₂ 88% on room air). Chest X-ray shows bilateral pulmonary infiltrates. Laboratory studies reveal WBC 45,000/μL (up from 8,000/μL at baseline), elevated LDH, and low fibrinogen. A bone marrow aspirate shows increased apoptotic bodies within leukaemic blasts. Which molecular pathway is predominantly activated by arsenic trioxide in inducing apoptosis of APL cells?

Explanation

## Mechanism of Arsenic Trioxide in APL **Key Point:** Arsenic trioxide (ATO) induces apoptosis in APL cells primarily through the **intrinsic (mitochondrial) pathway**, not the extrinsic pathway. ### Molecular Mechanism Arsenic trioxide acts through the following steps: 1. **ROS generation** — ATO increases reactive oxygen species (ROS) in mitochondria 2. **Mitochondrial stress** — ROS causes direct mitochondrial damage and oxidative stress 3. **MOMP activation** — Mitochondrial outer membrane permeabilization (MOMP) occurs 4. **Cytochrome c release** — Cytochrome c leaks into the cytoplasm 5. **Apoptosome formation** — Cytochrome c + Apaf-1 + pro-caspase-9 form the apoptosome 6. **Caspase-9 and caspase-3 activation** — Executioner caspases cleave PARP and other substrates **High-Yield:** ATO also causes **PML-RARA protein degradation** (the fusion protein in APL), which is an additional mechanism independent of apoptosis but synergistic with ATRA. ### Why Intrinsic, Not Extrinsic? | Pathway | Trigger | Key Proteins | Role of ATO | |---------|---------|--------------|-------------| | **Intrinsic** | Intracellular stress (ROS, DNA damage, hypoxia) | Bcl-2, Bax, Bak, cytochrome c, Apaf-1 | **ATO activates this** via ROS and mitochondrial damage | | **Extrinsic** | Death receptor ligation (Fas, TNF-R1) | Death receptors, DISC, caspase-8 | Not the primary ATO mechanism | | **Caspase-independent** | Severe mitochondrial damage | AIF, EndoG | Secondary pathway; not primary | **Clinical Pearl:** The clinical presentation described (fever, dyspnoea, infiltrates, rising WBC, low fibrinogen) is **differentiation syndrome (DS)** — a consequence of rapid leukaemic cell death and cytokine release, not a contraindication to continuing ATO. **Mnemonic:** **ATRA + ATO = Intrinsic** — Both ATRA and ATO converge on mitochondrial apoptosis in APL, making the intrinsic pathway the dominant mechanism. [cite:Robbins 10e Ch 7] ### Distinction from Extrinsic Pathway The extrinsic pathway (death receptors → DISC → caspase-8) is activated by ligands like FasL, TNF-α, and TRAIL. While some chemotherapy agents can upregulate death receptors, ATO's primary mechanism is ROS-mediated mitochondrial damage, which is intrinsic.